Inicio>>Signaling Pathways>> MAPK Signaling>> PKA>>CCG215022

CCG215022

Catalog No.GC19090

CCG215022 es un inhibidor de las quinasas del receptor acoplado a proteÍna G (GRK) con IC50 de 0,15 ± 0,07 μM, 0,38 ± 0,06 μM y 3,9 ± 1 μM para GRK2, GRK5 y GRK1, respectivamente.

Products are for research use only. Not for human use. We do not sell to patients.

CCG215022 Chemical Structure

Cas No.: 1813527-81-9

Tamaño Precio Disponibilidad Cantidad
1mg
94,00 $
Disponible
5mg
235,00 $
Disponible
10mg
335,00 $
Disponible
50mg
1.004,00 $
Disponible
100mg
1.406,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com

Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

CCG215022 is a G protein-coupled receptor kinases (GRKs) inhibitor with IC50s of 0.15±0.07 uM, 0.38±0.06 uM and 3.9±1 uM for GRK2, GRK5 and GRK1, respectively.

CCG215022 has nanomolar potency against both GRK2 and GRK5 and is at least 20-fold more potent than Paroxetine. In the course of a GRK2 structure-based drug design campaign, CCG215022 exhibits nanomolar IC50 values against both GRK2 and GRK5 and good selectivity against other closely related kinases such as GRK1 and PKA. Treatment of murine cardiomyocytes with CCG215022 results in significantly increases contractility at 20-fold lower concentrations than Paroxetine, an inhibitor with more modest selectivity for GRK2[1].

References:
[1]. Homan KT, et al. Crystal Structure of G Protein-coupled Receptor Kinase 5 in Complex with a Rationally DesignedInhibitor. J Biol Chem. 2015 Aug 21;290(34):20649-59.

Reseñas

Review for CCG215022

Average Rating: 5 ★★★★★ (Based on Reviews and 21 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for CCG215022

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.